Ton Rabelink

Biography

Ton Rabelink completed his medical studies in 1986 at the University of Utrecht, the Netherlands (cum laude). After earning his doctorate in the field of renal physiology, he qualified in internal medicine (1993), nephrology and vascular medicine (1995). In 1993, Ton Rabelink was awarded an academic grant from the Royal Academy of Science. As part of this funding, he was given the opportunity to work in the research laboratories of Prof. Lüscher at the University of Zurich and to further his education in the field of molecular biology. Upon his return to Utrecht in 2000, Rabelink was appointed Director of Medicine. In 2004 he moved to the University of Leiden and initially became head of nephrology and transplantation. Since 2010, Ton Rabelink is Director of Medicine of the Medical Center of Leiden University. Ton Rabelink veröffentlichte über 300 Artikel in Peer-Review-Zeitschriften. Sein gegenwärtiges Forschungsinteresse liegt im Bereich der Gefässbiologie, insbesondere der Rolle des Endothels bei gefässbiologischen Prozessen und im Bereich der Zelltherapie, wo der Fokus auf der klinischen Entwicklung von MSC und Beta-Zell-Therapie liegt. Ton Rabelink completed his medical studies in 1986 at the University of Utrecht, the Netherlands (cum laude). After earning his doctorate in the field of renal physiology, he qualified in internal medicine (1993), nephrology and vascular medicine (1995). In 1993, Ton Rabelink was awarded an academic grant from the Royal Academy of Science. As part of this funding, he was given the opportunity to work in the research laboratories of Prof. Lüscher at the University of Zurich and to further his education in the field of molecular biology. Upon his return to Utrecht in 2000, Rabelink was appointed Director of Medicine. In 2004 he moved to the University of Leiden and initially became head of nephrology and transplantation. Since 2010, Ton Rabelink is Director of Medicine of the Medical Center of Leiden University. Ton Rabelink veröffentlichte über 300 Artikel in Peer-Review-Zeitschriften. Sein gegenwärtiges Forschungsinteresse liegt im Bereich der Gefässbiologie, insbesondere der Rolle des Endothels bei gefässbiologischen Prozessen und im Bereich der Zelltherapie, wo der Fokus auf der klinischen Entwicklung von MSC und Beta-Zell-Therapie liegt.

Research Interest

Focused on cardiovascular research.